Deep Learning in Pharmacogenomics: From Gene Regulation to Patient Stratification

  title={Deep Learning in Pharmacogenomics: From Gene Regulation to Patient Stratification},
  author={Alexandr A Kalinin and Gerald A. Higgins and Narathip Reamaroon and S. Mohamad R. Soroushmehr and Ari Allyn-Feuer and Ivo D. Dinov and Kayvan Najarian and Brian D. Athey},
  volume={19 7},
This Perspective provides examples of current and future applications of deep learning in pharmacogenomics, including: identification of novel regulatory variants located in noncoding domains of the genome and their function as applied to pharmacoepigenomics; patient stratification from medical records; and the mechanistic prediction of drug response, targets and their interactions. Deep learning encapsulates a family of machine learning algorithms that has transformed many important subfields… 

Figures and Tables from this paper

Deep learning of pharmacogenomics resources: moving towards precision oncology

This review provides an in-depth summary of state-of-the-art DL methods and up-to-date pharmacogenomics resources and future opportunities and challenges to realize the goal of precision oncology.

Predicting drug response of tumors from integrated genomic profiles by deep neural networks

The first DNN model to translate pharmacogenomics features identified from in vitro drug screening to predict the response of tumors is presented and the model and findings improve the prediction of drug response and the identification of novel therapeutic options.

Pharmacogenomics at the center of precision medicine: challenges and perspective in an era of Big Data.

The principles artificial intelligence are proposed to apply to develop a medication optimization platform to prevent, manage and treat different diseases.

Variant discovery using next-generation sequencing and its future role in pharmacogenetics.

The role of NGS in variant discovery is discussed, paving the way for more comprehensive genotype-guided pharmacotherapy that can translate to improved clinical care.

TranSynergy: Mechanism-driven interpretable deep neural network for the synergistic prediction and pathway deconvolution of drug combinations

A knowledge-enabled and self-attention boosted deep learning model, TranSynergy is developed to improve the performance and interpretability of synergistic drug combinations prediction and significantly outperforms the state-of-the-art method, suggesting the potential of mechanism-driven machine learning.

Artificial intelligence for precision medicine in neurodevelopmental disorders

The ambition of precision medicine is to design and optimize the pathway for diagnosis, therapeutic intervention, and prognosis by using large multidimensional biological datasets that capture

Translating cancer genomics into precision medicine with artificial intelligence: applications, challenges and future perspectives

The current status and future directions of AI application in cancer genomics are reviewed within the context of workflows to integrate genomic analysis for precision cancer care and the unprecedented challenges posed should be addressed to ensure safety and beneficial impact to healthcare.

Computational Methods for the Pharmacogenetic Interpretation of Next Generation Sequencing Data

It is anticipated that these methodologies will provide a useful toolkit to facilitate the integration of the vast extent of rare genetic variability into drug response predictions in a precision medicine framework.

Artificial Neural Networks

An overview of the integrative mutation analysis platform is presented, which focuses on refining the current genotype–phenotype correlation methods by using the wealth of protein structural information.

Deep learning in cancer diagnosis, prognosis and treatment selection

This review provides an overview of emerging deep learning techniques and how they are being applied to oncology, and focuses on the deep learning applications for omics data types, including genomic, methylation and transcriptomic data, as well as histopathology-based genomic inference.



DeepMetabolism: A Deep Learning System to Predict Phenotype from Genome Sequencing

DeepMetabolism, a biology-guided deep learning system to predict cell phenotypes from transcriptomics data, is developed to bridge the gap between genotype and phenotype and to serve as a springboard for applications in synthetic biology and precision medicine.

Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug Repurposing Using Transcriptomic Data.

This work demonstrates a deep learning neural net trained on transcriptomic data to recognize pharmacological properties of multiple drugs across different biological systems and conditions and proposes using deep neural net confusion matrices for drug repositioning.

Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives

  • J. Patel
  • Biology, Medicine
    Pharmacogenomics and personalized medicine
  • 2016
This review provides an update on cancer pharmacogenomics and genomics-based medicine, challenges in applying Pharmacogenomics to the clinical setting, and patient perspectives on the use of pharmacogenetics to personalize cancer therapy.

Pharmacogenomics in clinical practice and drug development

Adoption of GWAS, exome or whole genome sequencing by drug development and treatment programs is the most striking near-term opportunity for improving the drug candidate pipeline and boosting the efficacy of medications already in use.

Machine Learning in Genomic Medicine: A Review of Computational Problems and Data Sets

An introduction to machine learning tasks that address important problems in genomic medicine by focusing on how machine learning can help to model the relationship between DNA and the quantities of key molecules in the cell, with the premise that these quantities may be associated with disease risks.

Deep Learning and Association Rule Mining for Predicting Drug Response in Cancer. A Personalised Medicine Approach

It is demonstrated that DLNNs trained on a large pharmacogenomics data-set can effectively predict the therapeutic response of specific drugs in different cancer types, a milestone in precision medicine.

DL-ADR: a novel deep learning model for classifying genomic variants into adverse drug reactions

A novel deep learning model based on generative stochastic networks and hidden Markov chain to classify the observed samples with SNPs on five loci of two genes respectively to the vulnerable population of 14 types of adverse reactions is presented.

Genomics and transcriptomics in drug discovery.

Pharmacogenomics in cardiology--genetics and drug response: 10 years of progress.

The Translational Pharmacogenetics Project was formed as a network-wide PGRN effort to translate actionable pharmacogenetic discoveries into clinical practice, and the NIH-funded Implementing Genomics in Practice Network was formed to further enhance and accelerate the incorporation of genomic information into clinical care.